Abstract:Objective To investigate the effect of sakubatrevalsartan on cardiac function after emergency percutaneous coronary intervention(PCI) in patients with acute myocardial infarction(AMI). Methods A total of 100 AMI patients receiving PCI from May 2017 to May 2019 were selected and randomly divided into the observation group (n=50) and the control group (n=50).Enalapril was used in control group, and sakubatrevalsartan was given in observation group.The clinical efficacy and ECG changes before PCI, 4 h and 7 d after PCI were compared between two groups.The changes of serum N-terminal B-type natriuretic peptide (NT-proBNP), left ventricular ejection fraction (LVEF), left ventricular end diastolic volume (LVEDV) immediately after operation and 6 months after operation, and adverse events during 6 months after PCI were observed and compared between two groups. Results After PCI, the cardiac function in observation group was significantly better than that in control group (96.00% vs 84.00%, P<0.05).At 4 h and 7 d after operation, the level of ST segment of ECG in observation group was significantly lower than that in control group (P<0.05).At 6 months after operation, LVEDV and NT-proBNP significantly decreased, and LVEF significantly increased compared with those immediately after operation in two groups (all P<0.05); LVEDV and NT-proBNP in observation group were significantly lower than those in control group, and LVEF was significantly higher than that in control group(P<0.05).The total incidence of adverse events in observation group was significantly lower than that in control group (6.00% vs 24.00%, P<0.05). Conclusion Sakubatrevalsartan can obviously improve the clinical effect of AMI patients treated by PCI and postoperative cardiac function, reduce the incidence of adverse events.